Frankenstein Cas9: engineering improved gene editing systems.

Gene Editing CRISPR-Cas Systems RNA, Guide, Kinetoplastida / genetics Endonucleases / genetics
CRISPR designer Cas9 enzyme design gene editing protein engineering synthetic biology

Journal

Biochemical Society transactions
ISSN: 1470-8752
Titre abrégé: Biochem Soc Trans
Pays: England
ID NLM: 7506897

Informations de publication

Date de publication:
31 10 2022
Historique:
received: 20 09 2022
revised: 12 10 2022
accepted: 14 10 2022
pubmed: 29 10 2022
medline: 3 11 2022
entrez: 28 10 2022
Statut: ppublish

Résumé

The discovery of CRISPR-Cas9 and its widespread use has revolutionised and propelled research in biological sciences. Although the ability to target Cas9's nuclease activity to specific sites via an easily designed guide RNA (gRNA) has made it an adaptable gene editing system, it has many characteristics that could be improved for use in biotechnology. Cas9 exhibits significant off-target activity and low on-target nuclease activity in certain contexts. Scientists have undertaken ambitious protein engineering campaigns to bypass these limitations, producing several promising variants of Cas9. Cas9 variants with improved and alternative activities provide exciting new tools to expand the scope and fidelity of future CRISPR applications.

Identifiants

DOI: 10.1042/BST20220873 PMID: 36305591
pubmed: 36305591
pii: 231998
doi: 10.1042/BST20220873
doi:

Substances chimiques

RNA, Guide 0
Endonucleases EC 3.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1505-1516

Informations de copyright

© 2022 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Auteurs

Pascal D Vos (PD)

Curtin Medical School, Curtin University, Bentley, Western Australia 6102, Australia.
Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia 6102, Australia.
Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands, Western Australia 6009, Australia.
ARC Centre of Excellence in Synthetic Biology, QEII Medical Centre, Nedlands, Western Australia 6009, Australia.
Centre for Medical Research, The University of Western Australia, Nedlands, Western Australia 6009, Australia.

Aleksandra Filipovska (A)

Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands, Western Australia 6009, Australia.
ARC Centre of Excellence in Synthetic Biology, QEII Medical Centre, Nedlands, Western Australia 6009, Australia.
Centre for Medical Research, The University of Western Australia, Nedlands, Western Australia 6009, Australia.
Telethon Kids Institute, Northern Entrance, Perth Children's Hospital, 15 Hospital Avenue, Nedlands, Western Australia 6009, Australia.
ORCID: 0000-0002-6998-8403

Oliver Rackham (O)

Curtin Medical School, Curtin University, Bentley, Western Australia 6102, Australia.
Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia 6102, Australia.
Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands, Western Australia 6009, Australia.
ARC Centre of Excellence in Synthetic Biology, QEII Medical Centre, Nedlands, Western Australia 6009, Australia.
Telethon Kids Institute, Northern Entrance, Perth Children's Hospital, 15 Hospital Avenue, Nedlands, Western Australia 6009, Australia.
ORCID: 0000-0002-5301-9624

Articles similaires

Generation of isogenic models of Angelman syndrome and Prader-Willi syndrome in CRISPR/Cas9-engineered human embryonic stem cells.

Rachel B Gilmore, Dea Gorka, Christopher E Stoddard et al.
1.00
Prader-Willi Syndrome Humans Angelman Syndrome CRISPR-Cas Systems Human Embryonic Stem Cells

Genome editing in Sub-Saharan Africa: a game-changing strategy for climate change mitigation and sustainable agriculture.

Peter Amoah, Abdoul-Razak Oumarou Mahamane, Moise Hubert Byiringiro et al.
1.00
Gene Editing Climate Change Africa South of the Sahara Crops, Agricultural Agriculture

Characterization of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina.

Satheesh Kumar, Yi-Wen Hsiao, Vickie H Y Wong et al.
1.00
Animals Humans CRISPR-Cas Systems Mice Vascular Endothelial Growth Factor A

Opportunities for CRISPR-Cas9 application in farm animal genetic improvement.

Dalia M Aboelhassan, Hesham Abozaid
1.00
Animals CRISPR-Cas Systems Gene Editing Animals, Genetically Modified Livestock

Classifications MeSH

questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Génie génétique › Édition de gène › Frankenstein Cas9: engineering improved gene...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Extinction de l'expression des gènes › Systèmes CRISPR-Cas › Frankenstein Cas9: engineering improved gene...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › ARN guide › Frankenstein Cas9: engineering improved gene...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Esterases › Endonucleases › Frankenstein Cas9: engineering improved gene...